Escitalopram Dose Optimization During Pregnancy: A PBPK Modeling Approach
Pharmaceutics · 17.10.2025 · 17 (10) · 1341
DOI: 10.3390/pharmaceutics17101341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 17.10.2025. Verfasst von Seo-Yeon Choi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, BK21 FOUR (Fostering Outstanding Universities for Research) program.
Abstract (Originalsprache)
Background/Objectives: Escitalopram, a first-line antidepressant, is primarily metabolized by CYP2C19. Its pharmacokinetics are altered during pregnancy. This study aims to predict maternal and fetal exposure to escitalopram during pregnancy and to propose safe and effective dosing strategies using physiologically based pharmacokinetic (PBPK) modeling.
Methods
Predictive PBPK models for escitalopram were developed in nonpregnant women, pregnant women, and the fetoplacental unit using the Simcyp® simulator. Additional models incorporating CYP2C19 phenotypes were constructed. Model performance was evaluated using visual predictive checks and by comparing predicted-to-observed ratios for the maximum plasma concentration (Cmax) and the area under the curve (AUC), within an acceptance criterion of 0.7–1.3.
Results
Escitalopram concentrations at doses of 10–20 mg declined with advancing gestation. The cord-to-maternal concentration ratio was approximately 0.70 for both doses. Simulations of maternal and fetoplacental PBPK models across CYP2C19 phenotypes showed that most observed concentrations fell within the 95% confidence intervals of the predictions. Based on the therapeutic range attained and the maintenance of steady-state exposure, a once-daily 20 mg escitalopram dose was predicted to be appropriate during pregnancy.
Conclusions
These findings suggest that a once-daily 20 mg dose appears optimal during pregnancy, highlighting the need to consider the gestational stage and CYP2C19 phenotype in dose optimization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94143, USA.
- Infectious Disease Healthcare, Kyungpook National University, Daegu 41566, Republic of Korea.
ORCID-Profile: Seo-Yeon Choi, Eunsol Yang, Kwang-Hee Shin
Förderung
- National Research Foundation of Korea
- BK21 FOUR (Fostering Outstanding Universities for Research) program
Zitieren
APA
Choi, S. Y., Yang, E., & Shin, K. H. (2025). Escitalopram Dose Optimization During Pregnancy: A PBPK Modeling Approach. Pharmaceutics, 17(10), 1341. https://doi.org/10.3390/pharmaceutics17101341
Vancouver
Choi SY, Yang E, Shin KH. Escitalopram Dose Optimization During Pregnancy: A PBPK Modeling Approach. Pharmaceutics. 2025;17(10):1341. doi:10.3390/pharmaceutics17101341
BibTeX
@article{Choi2025,
author = {Choi, Seo-Yeon and Yang, Eunsol and Shin, Kwang-Hee},
title = {Escitalopram Dose Optimization During Pregnancy: A PBPK Modeling Approach},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {10},
pages = {1341},
doi = {10.3390/pharmaceutics17101341}
}
EUVIMED